Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study
- PMID: 20653354
- DOI: 10.1592/phco.30.8.787
Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study
Abstract
Study objective: To investigate the potential impact of proton pump inhibitors (PPIs) on the effectiveness of clopidogrel in preventing recurrent ischemic events after percutaneous coronary intervention (PCI) with stent placement.
Design: Population-based, retrospective cohort study.
Data source: National medical and pharmacy benefit claims database comprising approximately 19 million members.
Patients: A total of 16,690 patients who had undergone PCI with stent placement and who were highly adherent to clopidogrel therapy alone (9862 patients) or to clopidogrel with a PPI (6828 patients) between October 1, 2005, and September 30, 2006.
Measurements and main results: The primary end point was the occurrence of a major adverse cardiovascular event during the 12 months after stent placement. These events were defined as hospitalization for a cerebrovascular event (stroke or transient ischemic attack), an acute coronary syndrome (myocardial infarction or unstable angina), coronary revascularization (PCI or coronary artery bypass graft), or cardiovascular death. A composite event rate was compared between patients who received clopidogrel alone and those who received concomitant clopidogrel-PPI therapy. Baseline differences in covariates were adjusted by using Cox proportional hazards models. In the 9862 patients receiving clopidogrel alone, 1766 (17.9%) experienced a major adverse cardiovascular event compared with 1710 patients (25.0%) who received concomitant clopidogrel-PPI therapy (adjusted hazard ratio 1.51, 95% confidence interval 1.39-1.64, p<0.0001). Similar associations of increased risk were observed for each PPI studied (omeprazole, esomeprazole, pantoprazole, and lansoprazole).
Conclusion: Concomitant use of a PPI and clopidogrel compared with clopidogrel alone was associated with a higher rate of major adverse cardiovascular events within 1 year after coronary stent placement.
Similar articles
-
Clinical outcomes in patients with the concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention: an analysis from the Guthrie Health Off-Label Stent (GHOST) investigators.Circ Cardiovasc Interv. 2011 Apr 1;4(2):162-70. doi: 10.1161/CIRCINTERVENTIONS.110.958884. Epub 2011 Mar 8. Circ Cardiovasc Interv. 2011. PMID: 21386091
-
Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation.Thromb Haemost. 2010 Dec;104(6):1211-8. doi: 10.1160/TH10-04-0218. Epub 2010 Oct 12. Thromb Haemost. 2010. PMID: 20941464
-
Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention.Am J Cardiol. 2011 Mar 15;107(6):871-8. doi: 10.1016/j.amjcard.2010.10.073. Epub 2011 Jan 19. Am J Cardiol. 2011. PMID: 21247527
-
Inhibition of the antithrombotic effects of clopidogrel by proton pump inhibitors: facts or fancies?Eur J Intern Med. 2010 Dec;21(6):484-9. doi: 10.1016/j.ejim.2010.08.004. Epub 2010 Sep 16. Eur J Intern Med. 2010. PMID: 21111931 Review.
-
Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel.Aliment Pharmacol Ther. 2010 Apr;31(8):810-23. doi: 10.1111/j.1365-2036.2010.04247.x. Epub 2010 Jan 22. Aliment Pharmacol Ther. 2010. PMID: 20102352 Review.
Cited by
-
A network meta-analysis: evaluating the efficacy and safety of concurrent proton pump inhibitors and clopidogrel therapy in post-PCI patients.Front Cardiovasc Med. 2024 Jul 24;11:1385318. doi: 10.3389/fcvm.2024.1385318. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 39114562 Free PMC article.
-
CYP2C19 loss-of-function alleles and use of omeprazole or esomeprazole increase the risk of cardiovascular outcomes in patients using clopidogrel.Clin Transl Sci. 2023 Oct;16(10):2010-2020. doi: 10.1111/cts.13608. Epub 2023 Aug 16. Clin Transl Sci. 2023. PMID: 37551775 Free PMC article.
-
Clinical Outcomes of Concomitant Use of Proton Pump Inhibitors and Dual Antiplatelet Therapy: A Systematic Review and Meta-Analysis.Front Pharmacol. 2021 Aug 2;12:694698. doi: 10.3389/fphar.2021.694698. eCollection 2021. Front Pharmacol. 2021. PMID: 34408652 Free PMC article.
-
Ethnic variance on long term clinical outcomes of concomitant use of proton pump inhibitors and clopidogrel in patients with stent implantation: A PRISMA-complaint systematic review with meta-analysis.Medicine (Baltimore). 2021 Feb 12;100(6):e24366. doi: 10.1097/MD.0000000000024366. Medicine (Baltimore). 2021. PMID: 33578533 Free PMC article.
-
Are There Different Evidence Thresholds for Genomic Versus Clinical Precision Medicine? A Value of Information-Based Framework Applied to Antiplatelet Drug Therapy.Value Health. 2019 Sep;22(9):988-994. doi: 10.1016/j.jval.2019.03.023. Epub 2019 Aug 1. Value Health. 2019. PMID: 31511188 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous